

Communiqué

<http://www.wpsgha.com>

ITEMS OF IMPORTANCE

Subscribe to WPS GHA Medicare eNews
to Stay Up to Date - Sign Up Today!2

COVERAGE – LOCAL COVERAGE

DETERMINATIONS AND COVERAGE

ARTICLES

Information on Website.....	3
New Policies	3
Retired Policies.....	5
Revised Policies	6

PROVIDER EDUCATION

Education Schedule.....	17
Medicare Learning Network (MLN).....	19
Quarterly Provider Update	20

MLN CONNECTS

MLN Connects® Newsletters	21
---------------------------------	----

Share this bulletin with all health care practitioners and managerial members of the provider staff. Our website makes bulletins available at no cost:

<https://www.wpsgha.com/wps/portal/mac/site/training/guides-and-resources/communiqué>

Current Procedural Terminology (CPT) is copyright 2018 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values, or related listings are included in CPT. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS restrictions apply to government use. Current Dental Terminology copyright © 2002, 2005 American Dental Association. All rights reserved.

Items of Importance

SUBSCRIBE TO WPS GHA MEDICARE ENEWS TO STAY UP TO DATE - SIGN UP TODAY!

WPS GHA offers the convenience of eNews (an electronic newsletter sent to you via email) to all providers in our jurisdiction. When you subscribe to WPS GHA Medicare eNews, you will receive the latest Medicare news in your email box. You may unsubscribe at any time, and we will never disclose, give, sell, or transfer your personally identifiable information to third parties.

WPS GHA Medicare eNews announces publication of the following:

- Time-sensitive national and local Medicare news
- Medicare program changes
- Policy updates, including new, retired, and revised policies
- Training events (including seminars, teleconferences, webinars, and on-demand trainings)
- *Communiqué* (quarterly newsletter)
- Specialty- and service-specific educational articles
- Much, much more

CMS and WPS GHA encourage all individuals to subscribe. We don't restrict subscriptions. Sign up today! Visit our website to subscribe (<https://corp-ws.wpsic.com/apps/commercial/unauth/medicareListservUserWelcomeLoadAction.do>).

Coverage – Local Coverage Determinations and Coverage Articles

INFORMATION ON WEBSITE

WPS GHA publishes Local Coverage Determinations (LCDs) and Coverage Articles on its website: <https://www.wpsgha.com/wps/portal/mac/site/policies/guides-and-resources>

Having trouble getting access to the Internet? Many establishments offer free internet access for the price of a cup of coffee. You can request a hard copy of a retired LCD by writing to our Freedom of Information (FOI) Unit:

<https://www.wpsgha.com/wps/portal/mac/site/training/guides-and-resources/freedom-of-information>



NEW POLICIES/ARTICLES

Below we list new policies/articles. Please note the effective date of the new policy/article. The policy/article will not appear as active until the effective date. Prior to the effective date, you can find the policy/article by selecting the link "Display Future Effective Documents" within the CMS Medicare Coverage Database (MCD):

<http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx>

Visit our website at the link below for more information:

<https://www.wpsgha.com/wps/portal/mac/site/policies/news-and-updates>

June 2019

We created no new policies/articles for June 2019.

May 2019

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
J5/J8	MoIDX: Microsatellite Instability-High (MSI-H) and Mismatch Repair Deficient (dMMR) Biomarker Coding and Billing Guidelines for Patients with Unresectable or Metastatic Solid Tumors	A56501	NA	06/10/2019
J5/J8	MoIDX: myPath Melanoma Assay	L37923	MoIDX-053	06/10/2019

April 2019

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
J5/J8	Billing and Coding Guidelines for Colonoscopy and Sigmoidoscopy-Diagnostic	A56394	NA	03/28/2019
<p>Change Request 10901 Local Coverage Determinations (LCDs): it will no longer be appropriate to include Current Procedure Terminology (CPT) codes or International Classification of Diseases Tenth Revision-Clinical Modification (ICD-10-CM) codes in the LCDs. All CPT & ICD-10 codes have been removed from LCD L34614 and placed into this associated billing & coding article linked to the LCD. There will not be a lapse in coverage.</p>				
J5/J8	Billing and Coding Guidelines for Endoscopic Treatment of GERD	A56395	NA	03/28/2019
<p>CMS National Coverage Policy: added Change Request 10901 Local Coverage Determinations (LCDs) Implementation date January 8, 2019. Change Request 10901 Local Coverage Determinations (LCDs): it will no longer be appropriate to routinely include Current Procedure Terminology (CPT) codes or International Classification of Diseases Tenth Revision-Clinical Modification (ICD-10-CM) codes in the LCDs. All codes removed from LCD L34659 Endoscopic Treatment of GERD have been placed in this billing & coding article linked to the LCD. CPT/HCPCS Codes, Group 1 Paragraph Non-covered Group 1 Codes: 43257 ESOPHAGOGASTRODUODENOSCOPY, FLEXIBLE, TRANSORAL; WITH DELIVERY OF THERMAL ENERGY TO THE MUSCLE OF LOWER ESOPHAGEAL SPHINCTER AND/OR GASTRIC CARDIA, FOR TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE, 43499 UNLISTED PROCEDURE, ESOPHAGUS, 43999 UNLISTED PROCEDURE, STOAMACH, and 49999 UNLISTED PROCEDURE, ABDOMEN, PERITONEUM AND OMENTUM. Group 2 Paragraph: EsophyX™ and Group 2 Codes: 43210 Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed. ICD-10 Codes that are Covered, Group 1 Paragraph: NA, Group 1 Codes XX000 Not Applicable. ICD-10 Codes that DO NOT Support Medical Necessity, Group 1 Paragraph: N/A, and Group 1 Codes: N/A. No lapse in coverage will occur.</p>				
J5/J8	Implantable Automatic Defibrillators - Coding and Billing	A56391	NA	05/13/2019
J5/J8	MolDX: Decipher® Biopsy Prostate Cancer Classifier Assay for Men with Very Low and Low Risk Disease	L37911	MolDX-048	05/13/2019

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
J5/J8	MoIDX: Envisia, Veracyte, Idiopathic Pulmonary Fibrosis Diagnostic Tes	L37919	MoIDX-051	05/13/2019
J5/J8	MoIDX: MDS FISH	L37772	MoIDX-044	05/13/2019

RETIRED POLICIES/ARTICLES

We retired the following policies/articles. Please be sure to note the effective date of the retired policy/article. It will not appear as retired until the effective date.

Visit our website at the link below for more information:

<https://www.wpsgha.com/wps/portal/mac/site/policies/news-and-updates>

June 2019

We retired no policies/articles for June 2019.

May 2019

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
J5/J8	Drugs and Biologics (Non-chemotherapy)	L34741	INJ-041	06/10/2019
	<p>This LCD and the associated Billing and Coding Guidelines will be retired 06/10/2019.</p> <p>The clinical information in this policy is available and supported by Federal Drug & Administration regulatory information.</p> <p>Drugs and biologics contained within in the policy will no longer be denied based on the language of the policy.</p> <p>Any drug or biologic billed to Medicare must be reasonable and medically necessary and meet the FDA indications.</p>			

April 2019

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
J5/J8	MoIDX: Breast Cancer Index SM Genetic Assay	L36785	MoIDX-005	04/14/2019
	<p>This LCD is being retired. It has been replaced with L37913 MoIDX: Breast Cancer IndexTM (BCI) Gene Expression Test.</p>			

REVISED POLICIES/ARTICLES

We revised the following policies/articles. Please be sure to note the effective date of the revised policy/article. The policy/article will not appear as active until the effective date. Prior to the effective date, you can find the policy/article by selecting the link "Display Future Effective Documents" within the CMS Medicare Coverage Database (MCD):

<http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx>

Visit our website at the link below for more information:

<https://www.wpsgha.com/wps/portal/mac/site/policies/news-and-updates>

June 2019

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
J5/J8	Billing and Coding: Human Granulocyte/Macrophage Colony Stimulating Factors	A56274	NA	05/30/2019
Please note title change: Billing and Coding: Human Granulocyte/Macrophage Colony Stimulating Factors				
ICD-10 Code Z79.899 Other long term (current) drug therapy added to: Group 8 Paragraph: Q5108 and Group 8 Codes, Group 9 Paragraph: Q5110 and Group 9 Codes, and Group 10 Paragraph: Q5111 and Group 10 Codes.				
J5/J8	MoIDX: bioTheranostics Cancer TYPE ID® Update	A55147	NA	07/14/2019
The following ICD-10 codes have been added to the Group 1 Paragraph and Group 1 codes:				
C02.1	Malignant neoplasm of border of tongue			
C08.9	Malignant neoplasm of major salivary gland, unspecified			
C09.9	Malignant neoplasm of tonsil, unspecified			
C11.8	Malignant neoplasm of overlapping sites of nasopharynx			
C15.3	Malignant neoplasm of upper third of esophagus			
C15.4	Malignant neoplasm of middle third of esophagus			
C15.5	Malignant neoplasm of lower third of esophagus			
C15.9	Malignant neoplasm of esophagus, unspecified			
C16.0	Malignant neoplasm of cardia			
C16.2	Malignant neoplasm of body of stomach			
C16.8	Malignant neoplasm of overlapping sites of stomach			
C16.9	Malignant neoplasm of stomach, unspecified			
C17.9	Malignant neoplasm of small intestine, unspecified			
C18.0	Malignant neoplasm of cecum			
C18.2	Malignant neoplasm of ascending colon			
C18.4	Malignant neoplasm of transverse colon			
C18.7	Malignant neoplasm of sigmoid colon			
C18.8	Malignant neoplasm of overlapping sites of colon			
C22.1	Intrahepatic bile duct carcinoma			

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
	C23	Malignant neoplasm of gallbladder		
	C24.8	Malignant neoplasm of overlapping sites of biliary tract		
	C24.9	Malignant neoplasm of biliary tract, unspecified		
	C25.0	Malignant neoplasm of head of pancreas		
	C25.1	Malignant neoplasm of body of pancreas		
	C26.9	Malignant neoplasm of ill-defined sites within digestive system		
	C31.9	Malignant neoplasm of accessory sinus, unspecified		
	C32.0	Malignant neoplasm of glottis		
	C32.8	Malignant neoplasm of overlapping sites of larynx		
	C34.00	Malignant neoplasm of unspecified male bronchus		
	C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung		
	C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung		
	C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus/lung		
	C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung		
	C37	Malignant neoplasm of thymus		
	C38.3	Malignant neoplasm of mediastinum, part unspecified		
	C38.4	Malignant neoplasm of pleura		
	C40.01	Malignant neoplasm of scapula and long bones of right upper limb		
	C40.02	Malignant neoplasm of scapula and long bones of left upper limb		
	C41.2	Malignant neoplasm of vertebral column		
	C41.3	Malignant neoplasm of ribs, sternum and clavicle		
	C41.9	Malignant neoplasm of bone and articular cartilage, unspecified		
	C43.39	Malignant melanoma of other parts of face		
	C43.4	Malignant melanoma of scalp and neck		
	C43.60	Malignant melanoma of unspecified upper limb, including shoulder		
	C43.61	Malignant melanoma of right upper limb, including shoulder		
	C43.62	Malignant melanoma of left upper limb, including shoulder		
	C43.9	Malignant melanoma of skin, unspecified		
	C44.222	Squamous cell carcinoma of skin of right ear, external auricular canal		
	C44.229	Squamous cell carcinoma of skin of left ear and external auricular canal		
	C44.329	Squamous cell carcinoma of skin and other parts of face		
	C44.399	Other malignant neoplasm of skin of other parts of face		
	C44.42	Squamous cell carcinoma of skin of scalp and neck		
	C44.49	Other specified malignant neoplasm of skin of scalp and neck		
	C44.501	Malignant neoplasm of skin of breast, unspecified		
	C44.509	Malignant neoplasm of skin of other part of trunk, unspecified		
	C44.521	Squamous cell carcinoma of skin of breast		
	C44.529	Squamous cell carcinoma of skin of other parts of trunk		
	C44.599	Other malignant neoplasm of skin of other part of trunk		
	C44.622	Squamous cell carcinoma of skin of right upper limb, including shoulder		

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
	C44.629	Squamous cell carcinoma of skin of left upper limb, including shoulder		
	C44.709	Malignant neoplasm of skin of lower limb, including hip, unspecified		
	C44.90	Malignant neoplasm of skin, unspecified		
	C44.92	Squamous cell carcinoma of skin, unspecified		
	C45.7	Mesothelioma of other sites		
	C48.1	Malignant neoplasm of specified parts of peritoneum		
	C48.2	Malignant neoplasm of peritoneum, unspecified		
	C48.8	Malignant neoplasm of overlapping sites of retroperitoneum/peritoneum		
	C49.12	Malignant neoplasm of connective/soft tissue of left upper limb, including shoulder		
	C49.5	Malignant neoplasm of connective and soft tissue of pelvis		
	C4A.71	Merkel cell carcinoma of right lower limb, including hip		
	C4A.9	Merkel cell carcinoma, unspecified		
	C50.111	Malignant neoplasm of central portion of right female breast		
	C50.112	Malignant neoplasm of central portion of left female breast		
	C50.211	Malignant neoplasm of upper inner quadrant of right female breast		
	C50.212	Malignant neoplasm of upper inner quadrant of left female breast		
	C50.311	Malignant neoplasms of lower-inner quadrant of right female breast		
	C50.312	Malignant neoplasm of lower inner quadrant of left female breast		
	C50.421	Malignant neoplasm of upper-outer quadrant of right male breast		
	C50.422	Malignant neoplasm of upper outer quadrant of left male breast		
	C50.611	Malignant neoplasm of axillary tail of right female breast		
	C50.612	Malignant neoplasm of axillary tail of left female breast		
	C50.819	Malignant neoplasm of overlapping sites of unspecified female breast		
	C50.919	Malignant neoplasm of unspecified site of unspecified female breast		
	C50.921	Malignant neoplasms of unspecified site of right male breast		
	C50.922	Malignant neoplasm of unspecified site of left male breast		
	C50.929	Malignant neoplasm of unspecified site of unspecified male breast		
	C53.0	Malignant neoplasm of endocervix		
	C53.8	Malignant neoplasm of overlapping sites of cervix uteri		
	C53.9	Malignant neoplasm of cervix uteri, unspecified		
	C54.1	Malignant neoplasm of endometrium		
	C54.3	Malignant neoplasm of fundus uteri		
	C54.9	Malignant neoplasm of corpus uteri, unspecified		
	C55	Malignant neoplasm of uterus, part unspecified		
	C56.9	Malignant neoplasm of unspecified ovary		
	C57.00	Malignant neoplasm of unspecified fallopian tube		
	C57.8	Malignant neoplasm of overlapping sites of female genital organs		
	C57.9	Malignant neoplasm of female genital organ, unspecified		
	C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis		
	C65.1	Malignant neoplasm of right renal pelvis		
	C65.2	Malignant neoplasms of left renal pelvis		
	C66.1	Malignant neoplasms of right ureter		

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
	C66.2	Malignant neoplasm of left ureter		
	C67.1	Malignant neoplasm of dome of bladder		
	C67.2	Malignant neoplasm of lateral wall of bladder		
	C67.4	Malignant neoplasm of posterior wall of bladder		
	C67.8	Malignant neoplasm of overlapping sites of bladder		
	C68.9	Malignant neoplasm of urinary organ, unspecified		
	C71.1	Malignant neoplasm of frontal lobe		
	C71.9	Malignant neoplasm of brain, unspecified		
	C73	Malignant neoplasm of thyroid gland		
	C74.90	Malignant neoplasm of unspecified part of unspecified adrenal gland		
	C74.92	Malignant neoplasm of unspecified part of left adrenal gland		
	C75.1	Malignant neoplasm of pituitary gland		
	C76.2	Malignant neoplasm of abdomen		
	C76.3	Malignant neoplasm of pelvis		
	C76.51	Malignant neoplasm of right lower limb		
	C76.52	Malignant neoplasm of left lower limb		
	C76.8	Malignant neoplasm of other specified ill-defined sites		
	C78.00	Secondary malignant neoplasm of unspecified lung		
	C78.1	Secondary malignant neoplasm of mediastinum		
	C78.2	Secondary malignant neoplasm of pleura		
	C78.4	Secondary malignant neoplasm of small intestine		
	C78.80	Secondary malignant neoplasm of unspecified digestive organ		
	C78.89	Secondary malignant neoplasm of other digestive organs		
	C79.60	Secondary malignant neoplasm of unspecified ovary		
	C79.70	Secondary malignant neoplasm of unspecified adrenal gland		
	C79.71	Secondary malignant neoplasm of right adrenal gland		
	C79.72	Secondary malignant neoplasm of left adrenal gland		
	C79.81	Secondary malignant neoplasm of breast		
	C79.82	Secondary malignant neoplasm of genital organs		
	C79.9	Secondary malignant neoplasm of unspecified site		
	C7A.00	Malignant carcinoid tumor of unspecified site		
	C7A.019	Malignant carcinoid tumor of small intestine, unspecified portion		
	C7A.090	Malignant carcinoid tumor of the bronchus and lung		
	C7A.1	Malignant poorly differentiated neuroendocrine tumors		
	C7A.8	Other malignant neuroendocrine tumors		
	C7B.02	Secondary carcinoid tumors of liver		
	C7B.03	Secondary carcinoid tumors of bone		
	C7B.8	Other secondary neuroendocrine tumors		
	C81.90	Hodgkin lymphoma, unspecified, unspecified site		
	C82.00	Follicular lymphoma grade I, unspecified site		
	C83.09	Small cell B cell lymphoma, extra nodal and solid organ sites		
	C83.10	Mantle cell lymphoma, unspecified site		
	C83.31	Diffuse large B cell lymphoma, lymph nodes of head, face, neck		
	C85.14	B Cell lymphoma, lymph nodes of axilla and upper limb, unspecified		
	C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site		
	C85.88	Other types of non-Hodgkin lymphoma, lymph nodes of multiple sites		

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date																																																				
	<table border="1"> <tr><td>C88.4</td><td>Extra nodal marginal zone B cell lymphoma of mucosa associated lymphoid tissue</td></tr> <tr><td>D37.6</td><td>Neoplasm of uncertain behavior of liver, gallbladder/bile ducts</td></tr> <tr><td>D37.8</td><td>Neoplasm of uncertain behavior of other digestive organs</td></tr> <tr><td>D37.9</td><td>Neoplasm of uncertain behavior of digestive organ, unspecified</td></tr> <tr><td>D38.1</td><td>Neoplasm of uncertain behavior of trachea, bronchus and lung</td></tr> <tr><td>D38.3</td><td>Neoplasm of uncertain behavior of mediastinum</td></tr> <tr><td>D41.01</td><td>Neoplasm of uncertain behavior of right kidney</td></tr> <tr><td>D48.0</td><td>Neoplasm of uncertain behavior of bone/articular cartilage</td></tr> <tr><td>D48.1</td><td>Neoplasm of uncertain behavior of connective/other soft tissue</td></tr> <tr><td>D48.3</td><td>Neoplasm of uncertain behavior of retroperitoneum</td></tr> <tr><td>D48.4</td><td>Neoplasm of uncertain behavior of peritoneum</td></tr> <tr><td>D48.5</td><td>Neoplasm of uncertain behavior of skin</td></tr> <tr><td>D48.61</td><td>Neoplasm of uncertain behavior of right breast</td></tr> <tr><td>D48.62</td><td>Neoplasm of uncertain behavior of left breast</td></tr> </table> <p data-bbox="342 884 1430 951">The following ICD-10 codes have been deleted from the Group 1 Paragraph and Group 1 Codes:</p> <table border="1"> <tr><td>C18.1</td><td>Malignant neoplasm of appendix</td></tr> <tr><td>C22.2</td><td>Hepatoblastoma</td></tr> <tr><td>C22.3</td><td>Angiosarcoma of liver</td></tr> <tr><td>C22.4</td><td>Other sarcomas of liver</td></tr> <tr><td>D01.5</td><td>Carcinoma in situ of liver, gallbladder and bile ducts</td></tr> <tr><td>D01.7</td><td>Carcinoma in situ of other specified digestive organs</td></tr> <tr><td>D01.9</td><td>Carcinoma in situ of digestive organ, unspecified</td></tr> <tr><td>D02.21</td><td>Carcinoma in situ of right bronchus and lung</td></tr> <tr><td>D02.22</td><td>Carcinoma in situ of left bronchus and lung</td></tr> <tr><td>D03.51</td><td>Melanoma in situ of anal skin</td></tr> <tr><td>D03.52</td><td>Melanoma in situ of breast (skin) (soft tissue)</td></tr> <tr><td>D03.59</td><td>Melanoma in situ of other part of trunk</td></tr> </table>	C88.4	Extra nodal marginal zone B cell lymphoma of mucosa associated lymphoid tissue	D37.6	Neoplasm of uncertain behavior of liver, gallbladder/bile ducts	D37.8	Neoplasm of uncertain behavior of other digestive organs	D37.9	Neoplasm of uncertain behavior of digestive organ, unspecified	D38.1	Neoplasm of uncertain behavior of trachea, bronchus and lung	D38.3	Neoplasm of uncertain behavior of mediastinum	D41.01	Neoplasm of uncertain behavior of right kidney	D48.0	Neoplasm of uncertain behavior of bone/articular cartilage	D48.1	Neoplasm of uncertain behavior of connective/other soft tissue	D48.3	Neoplasm of uncertain behavior of retroperitoneum	D48.4	Neoplasm of uncertain behavior of peritoneum	D48.5	Neoplasm of uncertain behavior of skin	D48.61	Neoplasm of uncertain behavior of right breast	D48.62	Neoplasm of uncertain behavior of left breast	C18.1	Malignant neoplasm of appendix	C22.2	Hepatoblastoma	C22.3	Angiosarcoma of liver	C22.4	Other sarcomas of liver	D01.5	Carcinoma in situ of liver, gallbladder and bile ducts	D01.7	Carcinoma in situ of other specified digestive organs	D01.9	Carcinoma in situ of digestive organ, unspecified	D02.21	Carcinoma in situ of right bronchus and lung	D02.22	Carcinoma in situ of left bronchus and lung	D03.51	Melanoma in situ of anal skin	D03.52	Melanoma in situ of breast (skin) (soft tissue)	D03.59	Melanoma in situ of other part of trunk			
C88.4	Extra nodal marginal zone B cell lymphoma of mucosa associated lymphoid tissue																																																							
D37.6	Neoplasm of uncertain behavior of liver, gallbladder/bile ducts																																																							
D37.8	Neoplasm of uncertain behavior of other digestive organs																																																							
D37.9	Neoplasm of uncertain behavior of digestive organ, unspecified																																																							
D38.1	Neoplasm of uncertain behavior of trachea, bronchus and lung																																																							
D38.3	Neoplasm of uncertain behavior of mediastinum																																																							
D41.01	Neoplasm of uncertain behavior of right kidney																																																							
D48.0	Neoplasm of uncertain behavior of bone/articular cartilage																																																							
D48.1	Neoplasm of uncertain behavior of connective/other soft tissue																																																							
D48.3	Neoplasm of uncertain behavior of retroperitoneum																																																							
D48.4	Neoplasm of uncertain behavior of peritoneum																																																							
D48.5	Neoplasm of uncertain behavior of skin																																																							
D48.61	Neoplasm of uncertain behavior of right breast																																																							
D48.62	Neoplasm of uncertain behavior of left breast																																																							
C18.1	Malignant neoplasm of appendix																																																							
C22.2	Hepatoblastoma																																																							
C22.3	Angiosarcoma of liver																																																							
C22.4	Other sarcomas of liver																																																							
D01.5	Carcinoma in situ of liver, gallbladder and bile ducts																																																							
D01.7	Carcinoma in situ of other specified digestive organs																																																							
D01.9	Carcinoma in situ of digestive organ, unspecified																																																							
D02.21	Carcinoma in situ of right bronchus and lung																																																							
D02.22	Carcinoma in situ of left bronchus and lung																																																							
D03.51	Melanoma in situ of anal skin																																																							
D03.52	Melanoma in situ of breast (skin) (soft tissue)																																																							
D03.59	Melanoma in situ of other part of trunk																																																							
J5/J8	<p data-bbox="342 1371 898 1472">MolDX: Targeted and Comprehensive Genomic Profile Next Generation Sequencing Testing in Cancer</p> <p data-bbox="342 1472 898 1577">Added a CPT/HCPCS Group 2 to the CPT/HCPCS Code section for billing clarification. CPT 81445 and 81479 were moved to Group 2. The revised CPT/HCPCS Groups are noted below.</p> <p data-bbox="342 1608 621 1640">CPT/HCPCS Codes</p> <p data-bbox="342 1640 1430 1707">Group 1 Paragraph: For myeloid malignancies utilizing Targeted Panels or CGP tests, relevant CPT/HCPCS codes include:</p> <p data-bbox="342 1707 574 1738">Group 1 Codes:</p> <table border="1"> <tr> <td data-bbox="342 1738 509 1879">81450</td> <td data-bbox="509 1738 1430 1879">TARGETED GENOMIC SEQUENCE ANALYSIS PANEL, HEMATOLYMPHOID NEOPLASM OR DISORDER, DNA ANALYSIS, AND RNA ANALYSIS WHEN PERFORMED, 5-50 GENES (EG, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2,</td> </tr> </table>	81450	TARGETED GENOMIC SEQUENCE ANALYSIS PANEL, HEMATOLYMPHOID NEOPLASM OR DISORDER, DNA ANALYSIS, AND RNA ANALYSIS WHEN PERFORMED, 5-50 GENES (EG, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2,	A55197	NA	04/25/2019																																																		
81450	TARGETED GENOMIC SEQUENCE ANALYSIS PANEL, HEMATOLYMPHOID NEOPLASM OR DISORDER, DNA ANALYSIS, AND RNA ANALYSIS WHEN PERFORMED, 5-50 GENES (EG, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2,																																																							

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
	JAK2, KRAS, KIT, MLL, NRAS, NPM1, NOTCH1), INTERROGATION FOR SEQUENCE VARIANTS, AND COPY NUMBER VARIANTS OR REARRANGEMENTS, OR ISOFORM EXPRESSION OR MRNA EXPRESSION LEVELS, IF PERFORMED			
	81479	UNLISTED MOLECULAR PATHOLOGY PROCEDURE		
	<p>CPT/HCPCS Codes Group 2 Paragraph: For solid tumors for Targeted Panels or CGP testing, relevant HCPCS/CPT codes include Group 2 Codes:</p>			
	81445	TARGETED GENOMIC SEQUENCE ANALYSIS PANEL, SOLID ORGAN NEOPLASM, DNA ANALYSIS, AND RNA ANALYSIS WHEN PERFORMED, 5-50 GENES (EG, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), INTERROGATION FOR SEQUENCE VARIANTS AND COPY NUMBER VARIANTS OR REARRANGEMENTS, IF PERFORMED		
	81479	UNLISTED MOLECULAR PATHOLOGY PROCEDURE		
	Added "Definitions:" above Targeted Tumor Panels.			
J5/J8	Psychiatry and Psychology Services	L34616	PSYCH-014	05/30/2019
	Added ICD-10 code F34.0, Cyclothymic Disorder, to Group 1 and Group 2 codes. Code was omitted during transition from ICD-9 to ICD-10. Effective 10/01/2015.			

May 2019

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
J5/J8	MoIDX: MammaPrint Billing and Coding Guidelines Update	A55175	NA	04/25/2019
	<p>The following information has been added to this article:</p> <p>The FDA decision summary gives the following intended use information: MammaPrint® is a qualitative in vitro diagnostic test service, performed in a single laboratory, using the gene expression profile of fresh frozen breast cancer tissue samples to assess a patients' risk for distant metastasis. The test is performed for breast cancer patients who are less than 61 years old, with Stage I or Stage II disease, with tumor size ≤ 5.0 cm and who are lymph node negative. The MammaPrint® result is indicated for use by physicians as a prognostic marker only, along with other clinicopathological factors.</p>			
J5/J8	MoIDX: Molecular Diagnostic Tests (MDT)	L36807	MoIDX-004	01/01/2019
	The following CPT codes have been added to this policy:			

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
	<p>0080U - Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy</p> <p>0081U - Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy - Effective 1/1/2019220, 3100081UOncology (uveal melanoma), mRNA, gene-expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping genes), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis</p> <p>0082U - Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions per date of service</p> <p>0083U - Oncology, response to chemotherapy drugs using motility contrast tomography, fresh or frozen tissue, reported as likelihood of sensitivity or resistance to drugs or drug combinations</p>			
J5/J8	<p>MolDX: Next Generation Sequencing Testing Coding and Billing Guidelines</p> <p>The title of this article has been changed to MolDX: Targeted and Comprehensive Genomic Profile Next Generation Sequencing Testing in Cancer</p> <p>The following sections have been updated:</p> <p>Targeted Tumor Panels Targeted Next-Generation Sequencing (NGS) panels are hereby defined as tests that identify somatic alterations known to occur in certain regions (i.e., 'hotspots') within specific genes of interest for cancer management (i.e., diagnosis, selection of molecularly targeted therapies, prognosis in a context where prognostic classification is essential for treatment selection). Generally, these NGS panels can detect single nucleotide variants (SNVs) and small insertions or deletions (INDELs) within these regions. These alterations typically represent response or lack of response to corresponding targeted cancer therapies. The hotspot test should include relevant regions in the genes required for companion diagnostic testing and/or known to be necessary for proper patient management.</p> <p>Comprehensive Genomic Profile (CGP) Testing CGP refers to NGS-based molecular assays that provide additional insight beyond individual gene hotspots; these assays seek to describe the genomic makeup of a tumor and can help identify underlying mechanisms of disease to guide clinical</p>	A55197	NA	04/25/2019

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
	<p>decision making. These tests include not only mutations in individual relevant genes, but also patterns of mutations across related genes in established cancer pathways and often include an assessment of overall mutational burden. These tests typically involve sequencing of entire exonic regions of genes of interest (within a comprehensive gene panel or whole exome sequencing), and may also include selected intronic regions. CGP can detect multiple types of molecular alterations (i.e., SNVs, small and large INDELS, copy number alterations (CNAs), structural variants (SVs), and splice-site variants) in a single assay. Patterns of mutations seen across multiple genes may be used to infer clinically relevant etiologies, such as DNA mismatch repair deficiency and microsatellite instability, and total mutational load/burden (TMB) may be determined. CGP testing may also include RNA sequencing to detect structural variations, such as translocations or large deletions, and to detect functional splicing mutations. CGP is not defined as a targeted panel by MoIDX.</p> <p>CPT coding Instructions CGP</p> <p>As CGP testing is not defined as a targeted panel by MoIDX, and it is a test not currently satisfactorily described by any existing CPT code. Therefore, to report a CGP service, test providers should use CPT code 81479 at this time, in addition to the approved DEX Z-Code™ for the test. Coverage of CGP is limited to one test per surgical specimen, and precludes the use of any other molecular testing on that specimen.</p> <p>For NGS-based tests that do not fit under the above definitions of “targeted” or “Comprehensive” panels, billing with the “Not Otherwise Classified” (NOC) code 81479 along with the approved DEX Z-Code™ identifier is appropriate.</p> <p>Diagnosis codes have been added for myeloid malignancies and solid tumors. See ICD-10 Codes that are Covered section. CPT code 81455 has been removed from this article.</p>			

April 2019

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
J5/J8	Colonoscopy and Sigmoidoscopy-Diagnostic	L34614	GI-006	03/28/2019
	Change Request 10901 Local Coverage Determinations (LCDs): it will no longer be appropriate to include Current Procedure Terminology (CPT) codes or International Classification of Diseases Tenth Revision-Clinical Modification (ICD-10-CM) codes in the LCDs. All CPT & ICD-10 codes have been removed from this LCD and placed into the associated Billing & coding article linked to this LCD. There will not be a lapse in coverage.			
J5/J8	Endoscopic Treatment of GERD	L34659	GI-010	03/28/2019

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
	<p>CMS National Coverage Policy: added Change Request 10901 Local Coverage Determinations (LCDs) Implementation date January 8, 2019.</p> <p>Change Request 10901 Local Coverage Determinations (LCDs): it will no longer be appropriate to include Current Procedure Terminology (CPT) codes or International Classification of Diseases Tenth Revision-Clinical Modification (ICD-10-CM) codes in the LCDs. All codes will be removed from LCDs and placed into billing & coding articles that are linked to the LCD.</p> <p>Removed CPT/HCPCS Codes, Group 1 Paragraph Non-covered Group 1 Codes: 43257 ESOPHAGOGASTRODUODENOSCOPY, FLEXIBLE, TRANSORAL; WITH DELIVERY OF THERMAL ENERGY TO THE MUSCLE OF LOWER ESOPHAGEAL SPHINCTER AND/OR GASTRIC CARDIA, FOR TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE,</p> <p>43499 UNLISTED PROCEDURE, ESOPHAGUS, 43999 UNLISTED PROCEDURE, STOAMACH, and 49999 UNLISTED PROCEDURE, ABDOMEN, PERITONEUM AND OMENTUM.</p> <p>Removed Group 2 Paragraph: EsophyX™ and Group 2 Codes: 43210 Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.</p> <p>Removed ICD-10 Codes that are Covered, Group 1 Paragraph: NA, Group 1 Codes XX000 Not Applicable.</p> <p>Removed ICD 10 Codes that DO NOT Support Medical Necessity, Group 1 Paragraph: N/A, and Group 1 Codes: N/A.</p> <p>Aforementioned CPT/HCPCS and ICD-10 Codes being placed into Billing and Coding Guidelines for Endoscopic Treatment of GERD effective 05/13/2019. No lapse in coverage will occur.</p>			
J5/J8	<p>Human Granulocyte/Macrophage Colony Stimulating Factors Billing and Coding Guidelines</p> <p>Correction required: Group 5 Paragraph: J2505: Indications for Pegfilgrastim (Neulasta™) Group 5 Code table: Removed incorrect code Z93.3 Colostomy status and Replaced with Z92.3 Personal history of irradiation.</p>	A56274	NA	03/19/2019
J5/J8	MoIDX: BDX-XL2	L37216	MoIDX-030	01/01/2019

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
	<p>Added 0080U and removed 81599- UNLISTED MULTIANALYTE ASSAY WITH ALGORITHMIC ANALYSIS. This revision is due to the 2019 Q1 CPT/HCPCS Updates and is effective 01/01/2019.</p> <p>0080U ONCOLOGY (LUNG), MASS SPECTROMETRIC ANALYSIS OF GALECTIN-3-BINDING PROTEIN AND SCAVENGER RECEPTOR CYSTEINE-RICH TYPE 1 PROTEIN M130, WITH FIVE CLINICAL RISK FACTORS (AGE, SMOKING STATUS, NODULE DIAMETER, NODULE-SPICULATION STATUS AND NODULE LOCATION), UTILIZING PLASMA, ALGORITHM REPORTED AS A CATEGORICAL PROBABILITY OF MALIGNANCY</p>			
J5/J8	MoIDX: Decision Dx-UM (Uveal Melanoma)	L37210	MoIDX-029	03/28/2019
	<p>Added 0081U and removed 81479 -Unlisted Molecular Pathology Procedure. The change is due to the Q1:2019 CPT/HCPCS Quarterly Update and is effective 01/01/2019</p> <p>0081U ONCOLOGY (UVEAL MELANOMA), MRNA, GENEEXPRESSION PROFILING BY REAL-TIME RT-PCR OF 15 GENES (12 CONTENT AND 3 HOUSEKEEPING GENES), UTILIZING FINE NEEDLE ASPIRATE OR FORMALIN-FIXED PARAFFINEMBEDDED TISSUE, ALGORITHM REPORTED AS RISK OF METASTASIS</p> <p>Deleted the Demirci reference in the Clinical Performance Validity Table</p>			
J5/J8	MoIDX: Myriad's BRACAnalysis CDx® Coding and Billing Guidelines	A55224	NA	05/13/2019
	<p>Added "men" to the following section:</p> <p>The FDA has approved Lynparza ® (olaparib), as a treatment for women with advanced ovarian cancer or women or men with metastatic breast cancer, and the companion diagnostic BRACAnalysis CDx ®, the laboratory test to detect mutated BRCA genes.</p> <p>For clarification, non-covered indications added:</p> <p>BRCA1/BRCA2 genetic testing is not reasonable and necessary, thus it is non-covered, for the following indications:</p> <ul style="list-style-type: none"> • Genetic screening in the general population. Such testing is considered screening and is excluded by Medicare statute. An ABN must be obtained for BRCA 1 and BRCA 2 testing for individuals without signs and symptoms of breast, ovarian or other hereditary cancer syndromes as indicated in this policy. • Testing of individuals with no personal history of breast, ovarian, fallopian tube, primary peritoneal, pancreatic, or prostate cancer. Such testing is considered screening and is excluded by Medicare statute. An ABN must 			

Contract	Title	CMS MCD Policy #	WPS Policy #	Effective Date
	<p>be obtained for BRCA 1 and BRCA 2 testing for individuals without signs and symptoms of breast, ovarian or other hereditary cancer syndromes as indicated in this policy</p> <ul style="list-style-type: none"> • Testing of individuals under 18 years of age. 			
J5/J8	<p>Wound Care Coding Companion for Wound Care</p> <p>Added CPT 97602 to Group One ICD-10 Codes that are Covered effective 05/13/2019.</p> <p>Removed national policy language from line item number 4 under Billing and Coding Guidelines for Wound Care due to Change Request 10901 Local Coverage Determinations (LCDs).</p> <p>Added link to CMS Publication 100-02, Medicare Coverage Policy Manual, Chapter 7 – Home Health Services, Section 10.11 and CMS IOM PUB 100-4, Medicare Claims Processing Manual Chapter 4, Section 200.9 - Billing for “Sometimes Therapy” Services that May be Paid as Non-Therapy Services for Hospital Outpatients under CMS Manual Explanations URL(s).</p> <p>Revised sentence Number 5 under Billing and Coding Guidelines for Wound Care for clarification as follows: For Part B, CPT code 97602 has been assigned a status indicator "B" (Bundled) in the Medicare Physician Fee Schedule Database (MPFSDB), meaning that it is not separately payable under Medicare Part B. For Part A, CPT code 97602 is designated as a “sometimes therapy” service.</p>	A55909	NA	05/13/2019
J5/J8	<p>Wound Care</p> <p>Removed national policy language from the sections: Electrical Stimulation and Electromagnetic Therapy and Topical Oxygen Therapy due to Change Request (CR) 10901 Local Coverage Determinations (LCDs).</p>	L37228	GSURG-056	03/28/2019

EDUCATION SCHEDULE

WPS GHA Learning Center

WPS GHA Provider Outreach & Education (POE) offers numerous educational opportunities in our Learning Center: <http://wpsghalearningcenter.com/store-catalog>. We offer on-demand learning, allowing you to access the education at your convenience. We also offer live events via seminar, teleconference, and webinar on many subjects. You can browse through and register for these events in the Learning Center. Our education offers Certificates of Achievements identifying the length of time of the education. You can use these certificates (without an index number) to receive Continuing Education Units (CEUs) from most accrediting organization.

We provide all educational materials in an electronic format. Please access and print the materials prior to the session. To locate, choose the Additional References tab within the individual course in our Learning Center.

Visit the WPS GHA Learning Center and look for the upcoming events that we are offering in 2019:

PART A OPPORTUNITIES:

Teleconferences

Provider Enrollment (PE) Series – This year WPS GHA highlights provider enrollment education. We created a series of teleconferences to assist various types of providers with the Medicare enrollment process. Topics range from an open Ask-the-Contractor (ACT) teleconference to sessions created for specific provider types. Check the WPS GHA Learning Center throughout the year to register for these teleconferences.

08/21/2019 — PE for Community Outpatient Rehab Facilities

12/18/2019 — PE for Community Mental Health Centers

Webinars

Skilled Nursing Facility (SNF) Series – WPS GHA will offer education on various topics relating to SNF Part A billing. We will hold the webinars every second Thursday of the month starting in April. For more information on each topic, check the WPS GHA Learning Center monthly to register for sessions.

06/13/2019 — Coding and Billing Benefits Exhaust/No-Pay Claims

07/11/2019 — SNF Billing Beyond the Basics

08/08/2019 — Patient Driven Payment Method (PDPM)/Minimum Data Set (MDS) Assessments

09/12/2019 — SNF Part B Billing

10/10/2019 — Patient Driven Payment Method (PDPM) Questions and Answers

11/14/2019 — SNF Consolidated Billing (CB)/Communications/Professional Services

12/12/2019 — SNF CB Institutional Services

In Person Events

Coming Soon – Medicare Day of Learning (MDL)

We designed the multi-session, single-day event to give participants control over their education. You can choose from 19 unique breakout sessions including appeals, telehealth, preventing denials, evaluation and management (E/M) for 2019, and so much more. The event contains six contact hours from 8:00 am to 4:00 pm followed by an optional question and answer session with the WPS GHA staff.

The MDL events are extremely popular and well attended. Please watch your eNews for registration information and mark your calendar for one of the following dates:

- 07/16/2019 — Century II Performing Arts & Convention Center — Wichita, Kansas
- 07/18/2019 — University Plaza Hotel and Convention Center — Springfield, Missouri
- 08/20/2019 — Delta Hotels Kalamazoo Conference Center — Kalamazoo, Michigan
- 08/22/2019 — Four Points by Sheraton — West Lafayette, Indiana

PART B OPPORTUNITIES:

Teleconferences

Provider Enrollment (PE) Series – This year WPS GHA highlights provider enrollment education. We created a series of teleconferences to assist various types of providers with the Medicare enrollment process. Topics range from an open Ask-the-Contractor (ACT) teleconference to sessions created for specific provider types. Check the WPS GHA Learning Center throughout the year to register for these teleconferences.

08/21/2019 — PE for Community Outpatient Rehab Facilities

11/20/2019 — PE for Rural Health Clinics

In Person Events

Coming Soon – Medicare Day of Learning (MDL)

We designed the multi-session, single-day event to give participants control over their education. You can choose from 19 unique breakout sessions including appeals, telehealth, preventing denials, evaluation and management (E/M) for 2019, and so much more. The event contains six contact hours from 8:00 am to 4:00 pm followed by an optional question and answer session with the WPS GHA staff.

The MDL events are extremely popular and well attended. Please watch your eNews for registration information and mark your calendar for one of the following dates:

- 07/16/2019 — Century II Performing Arts & Convention Center — Wichita, Kansas
- 07/18/2019 — University Plaza Hotel and Convention Center — Springfield, Missouri
- 08/20/2019 — Delta Hotels Kalamazoo Conference Center — Kalamazoo, Michigan

- 08/22/2019 — Four Points by Sheraton — West Lafayette, Indiana

In the Works

The WPS GHA Provider Outreach and Education Team is currently working on the following topics for upcoming education:

- Appeals
- Care Management
- Claims Review & Findings
- Critical Care
- Drug Screening
- Evaluation and Management 2019
- Hospital Notices
- Inpatient Psychiatric Facilities
- Medicare Resources
- Medicare Secondary Payer
- Preventing Part A Denials
- Skilled Nursing Facility Notices
- Expansion of Telehealth Services
- Wound Care

Continue to watch the Wednesday eNews for the most current education topics available.

MEDICARE LEARNING NETWORK (MLN)

We encourage you to visit the [Medicare Learning Network](http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/index.html) the place for official CMS Medicare fee-for-service provider educational information. There you can find one of our most popular products, MLN Matters national provider education articles. These articles help you understand new or changed Medicare policy and how those changes affect you. You can access a full array of other educational products (including Web-based training courses, hard copy and downloadable publications, and CD-ROMs) at: <http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/index.html>. You can also find other important Web sites by visiting the Physician Center Web page at: <http://www.cms.gov/Center/Provider-Type/Physician-Center.html>, and the All Fee-For-Service Providers Web page at: <https://www.cms.gov/Center/Provider-Type/All-Fee-For-Service-Providers-Center.html>.

In addition to educational products, the MLN also offers providers and suppliers opportunities to learn more about the Medicare program through MLN National Provider Calls. These national conference calls, held by CMS for the Medicare Fee-For-Service provider and supplier community, educate and inform participants about new policies and/or changes to the Medicare program. Offered free of charge, you can receive continuing education credits for participation in certain National Provider Calls. To learn more about MLN National Provider Calls including upcoming calls, registration information, and links to previous call materials, visit <http://www.cms.gov/Outreach-and-Education/Outreach/NPC/index.html>.

QUARTERLY PROVIDER UPDATE

The Centers for Medicare & Medicaid Services (CMS) publishes the Quarterly Provider Update on the first business day of each quarter. CMS publishes this comprehensive resource to make it easier for providers, suppliers, and the general public to understand proposed and implemented changes.

CMS publishes this update to inform the public about the following:

- Regulations and major policies completed or cancelled.
- New/Revised manual instructions

You can access the Quarterly Provider Update on the CMS website at:

<https://www.cms.gov/Regulations-and-Guidance/Regulations-and-Policies/QuarterlyProviderUpdates/index.html>.

We encourage you to bookmark this web page and visit it often for this valuable information. To receive notification when CMS adds regulations and program instructions throughout the quarter, sign up for the Quarterly Provider Update Listserv at:

https://public.govdelivery.com/accounts/USCMS/subscriber/new?topic_id=USCMS_460.

MLN CONNECTS® NEWSLETTERS

CMS compiles news from across the Agency into your single source for:

- CMS program and policy details
- Updates and announcements
- Press releases
- Upcoming educational event registration and reminders
- Claim, pricer, and code information
- Updates on new and revised MLN Publications

WPS GHA includes MLN Connects articles published during the previous quarter in the *Communiqué*. The information included in these articles is current at the time we publish the *Communiqué*. Changes may occur subsequent to publication.

To receive MLN Connects articles directly from CMS, sign up for email updates:

https://public.govdelivery.com/accounts/USCMS/subscriber/new?pop=t&topic_id=USCMS_7819

CMS published the following MLN Connects articles during the last quarter:

MLN Connects for May 23, 2019

<https://www.cms.gov/Outreach-and-Education/Outreach/FFSProvPartProg/Provider-Partnership-Email-Archive-Items/2019-05-23-eNews.html>

MLN Connects for May 16, 2019

<https://www.cms.gov/Outreach-and-Education/Outreach/FFSProvPartProg/Provider-Partnership-Email-Archive-Items/2019-05-16-eNews.html>

MLN Connects for May 9, 2019

<https://www.cms.gov/Outreach-and-Education/Outreach/FFSProvPartProg/Provider-Partnership-Email-Archive-Items/2019-05-09-eNews.html>

MLN Connects for May 2, 2019

<https://www.cms.gov/Outreach-and-Education/Outreach/FFSProvPartProg/Provider-Partnership-Email-Archive-Items/2019-05-02-eNews.html>

MLN Connects for April 25, 2019

<https://www.cms.gov/Outreach-and-Education/Outreach/FFSProvPartProg/Provider-Partnership-Email-Archive-Items/2019-04-25-eNews.html>

CMS Proposes 5 Rules Affecting FY20 Payment & Quality Programs

<https://www.cms.gov/Outreach-and-Education/Outreach/FFSProvPartProg/Provider-Partnership-Email-Archive-Items/2019-04-23-eNews-SE.html>

MLN Connects for April 18, 2019

<https://www.cms.gov/Outreach-and-Education/Outreach/FFSProvPartProg/Provider-Partnership-Email-Archive-Items/2019-04-18-eNews.html>

MLN Connects for April 11, 2019

<https://www.cms.gov/Outreach-and-Education/Outreach/FFSProvPartProg/Provider-Partnership-Email-Archive-Items/2019-04-11-eNews.html>

MLN Connects for April 4, 2019

<https://www.cms.gov/Outreach-and-Education/Outreach/FFSProvPartProg/Provider-Partnership-Email-Archive-Items/2019-04-04-eNews.html>

MLN Connects for March 28, 2019

<https://www.cms.gov/Outreach-and-Education/Outreach/FFSProvPartProg/Provider-Partnership-Email-Archive-Items/2019-03-28-eNews.html>

MLN Connects for March 21, 2019

<https://www.cms.gov/Outreach-and-Education/Outreach/FFSProvPartProg/Provider-Partnership-Email-Archive-Items/2019-03-21-eNews.html>

MLN Connects for March 14, 2019

<https://www.cms.gov/Outreach-and-Education/Outreach/FFSProvPartProg/Provider-Partnership-Email-Archive-Items/2019-03-14-eNews.html>

MLN Connects for March 7, 2019

<https://www.cms.gov/Outreach-and-Education/Outreach/FFSProvPartProg/Provider-Partnership-Email-Archive-Items/2019-03-07-eNews.html>

MLN Connects for February 28, 2019

<https://www.cms.gov/Outreach-and-Education/Outreach/FFSProvPartProg/Provider-Partnership-Email-Archive-Items/2019-02-28-eNews.html>

WPS GHA PROVIDER SERVICES

For additional information on the content of this newsletter, changes in policy or procedures, how to obtain a hardcopy of a Local Coverage Determination (LCD)/Coverage Article, or if you experience difficulties obtaining a policy/coverage article on our website, please contact a customer service representative at the telephone numbers/addresses listed below.

J5 MAC PART B (IA, KS, MO, NE)	
Iowa	Kansas
WPS GHA General Correspondence P.O. Box 8550 Madison, WI 53708-8550 (866) 518-3285	WPS GHA General Correspondence P.O. Box 7238 Madison, WI 53707-7238 (866) 518-3285
Missouri	Nebraska
WPS GHA General Correspondence P.O. Box 14260 Madison, WI 53708-0260 (866) 518-3285	WPS GHA General Correspondence P.O. 8667 Madison, WI 53708-8667 (866) 518-3285
J8 MAC PART B (IN, MI)	
Indiana	Michigan
WPS GHA General Correspondence P.O. Box 8580 Madison, WI 53708-8580 (866) 234-7331	WPS GHA General Correspondence P.O. Box 8939 Madison, WI 53708-8939 (866) 234-7331

VISIT THE WPS GHA WEBSITE FOR ALL YOUR MEDICARE NEEDS

WPS GHA would like to remind providers that the *Communiqué* does not include all the information needed by Medicare providers. While the publication does include general information, articles, and updates, the most comprehensive source of information is the WPS GHA website (<http://www.wpsgha.com/>). Visit us today!

WPS GHA MEDICARE eNEWS MESSAGES

Stay up-to-date on Medicare issues by signing up for WPS GHA Medicare eNews. By subscribing, you will enjoy an easy and secure way to stay current on the latest Medicare news, with the option to unsubscribe at any time. To receive our eNews messages, go to <https://corp-ws.wpsic.com/apps/commercial/unauth/medicareListservUserWelcomeLoadAction.do>. Follow the site's instructions for signing up and simply check your email regularly to receive the latest Medicare information.